<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00623519</url>
  </required_header>
  <id_info>
    <org_study_id>AST-ANA-2004-01</org_study_id>
    <nct_id>NCT00623519</nct_id>
  </id_info>
  <brief_title>Assessment of Endometrial Changes in Postmenopausal Women With Breast Cancer in Adjuvant Treatment With Anastrozole</brief_title>
  <official_title>Assessment of Endometrial Changes in Postmenopausal Women With Breast Cancer in Adjuvant Treatment With Anastrozole.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      To investigate the global incidence of the endometrial changes in postmenopausal women
      receiving Anastrozole for the adjuvant treatment of hormone receptors positive breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Global incidence of endometrial changes during the adjuvant treatment with Anastrozole</measure>
    <time_frame>From inclusion to treatment end(5 years duration) measurements will be taken annually, with a further assessment 12 months after end of treatment.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To describe the endometrial changes both clinically(vaginal bleeding) and through the scan.</measure>
    <time_frame>During the study, at least annually</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histological assessment when indicated(type of hyperplasia)</measure>
    <time_frame>When applicable</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess global incidence of endometrial changes in this patient population before taking Anastrozole</measure>
    <time_frame>During the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate type of surgery required for endometrial changes control(hysterectomy rate)</measure>
    <time_frame>During the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess treatment tolerability</measure>
    <time_frame>During the study</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">165</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Women with hormone receptor positive breast cancer under adjuvant treatment with Anastrozole</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Medical Oncology
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of Informed Consent

          -  Resectable breast cancer patients, with histological confirmation

          -  Patients eligible to receive hormonal adjuvant treatment with Anastrozole

          -  They are allowed patients treated with adjuvant chemo or radiotherapy concurrently

          -  Patients previously treated with Tamoxifen that had to withdraw treatment due to other
             reason than endometrial changes are allowed

          -  Postmenopausal patients(aged 50 years or over/ without menses in the last months/ FSH
             level &gt;40UI/L / women under 50 years with FSH levels&gt;40UI/L).

          -  Women showing progesterone and/or estrogen receptors positive.

        Exclusion Criteria:

          -  Patients with evidence of metastatic disease

          -  Patients unsuitable to receive the medication according the Anastrozole label

          -  Patients not giving their Informed Consent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rosana Cajal, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca Spain</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Coru√±a</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Granada</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Huelva</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ibiza</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jerez</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>La Rioja</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lugo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Malaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mallorca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pontevedra</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santander</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2008</study_first_submitted>
  <study_first_submitted_qc>February 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2008</study_first_posted>
  <last_update_submitted>March 6, 2009</last_update_submitted>
  <last_update_submitted_qc>March 6, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 9, 2009</last_update_posted>
  <responsible_party>
    <name_title>Rosana Cajal, MD - Medical Director</name_title>
    <organization>AstraZeneca Spain</organization>
  </responsible_party>
  <keyword>Adjuvant postmenopausal breast cancer women</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anastrozole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

